Single-dose vaccine against tick-borne encephalitis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 32, 2013, Pages 13103-13108

  Rumyantsev, Alexander A ^a   Goncalvez, Ana P ^a   Giel Moloney, Maryann ^a   Catalan, John ^a   Liu, Yuxi ^a   Gao, Qing Sheng ^a   Almond, Jeff ^a   Kleanthous, Harry ^a   Pugachev, Konstantin V ^a  

^a SANOFI PASTEUR   (France)

Author keywords

Flavivirus vaccine; Nonhuman primate; Preclinical; Prophylaxis

Indexed keywords

LIVE VACCINE; REPLIVAX; TICK BORNE ENCEPHALITIS VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHIMERA; CONTROLLED STUDY; DENGUE VIRUS 2; ENVELOPE GENE; GENE DELETION; GENETIC STABILITY; HELPER CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SINGLE DRUG DOSE; TICK BORNE ENCEPHALITIS; TICK BORNE FLAVIVIRUS; VIROGENESIS; WEST NILE FLAVIVIRUS; YELLOW FEVER FLAVIVIRUS;

FLAVIVIRUS VACCINE; NONHUMAN PRIMATE; PRECLINICAL; PROPHYLAXIS;

ANIMALS; ANTIBODIES, VIRAL; CELL LINE; CERCOPITHECUS AETHIOPS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENCEPHALITIS VIRUSES, TICK-BORNE; ENCEPHALITIS, TICK-BORNE; HOST-PATHOGEN INTERACTIONS; HUMANS; MACACA MULATTA; MICE; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; VACCINATION; VACCINES, ATTENUATED; VACCINES, INACTIVATED; VERO CELLS; VIRAL VACCINES;

EID: 84881452902     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1306245110     Document Type: Article

References (37)

1. World Health Organization (2011) Vaccines against tick-borne encephalitis: WHO position paper. Wkly Epidemiol Rec 86(24):241-256.
2. Barrett PN, Plotkin SA, Ehrlich HJ (2008) Vaccines, eds Plotkin SA, Orenstein WA (Elsevier Saunders, Offit, PA), 5th Ed, pp 841-856.
3. Kunze U; International Scientific Working Group on Tick-Borne Encephalitis (2011) Tick-borne encephalitis: New paradigms in a changing vaccination environment. Wien Med Wochenschr 161(13-14):361-364.
4. Burke DS, Monath TP (2001) Flaviviruses. Fields Virology, eds Knipe DM, et al. (Lippincott Williams and Wilkins, Philadelphia), 4th Ed, pp 1043-1126.
5. Lindenbach BD, Thiel H-J, Rice CM (2007) Flaviviridae: The viruses and their replication. Fields Virology, eds Knipe DM, et al. (Lippincott Williams and Wilkins, Philadelphia), 5th Ed, pp 1101-1152.
6. Pugachev KV, Guirakhoo F, Trent DW, Monath TP (2010) New generation vaccines, eds Levine MM, et al. (Informa Healthcare, New York), 4th Ed, pp 557-569.
7. Guy B, et al. (2010) Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 28(3): 632-649.
8. Smorodincev AA, Dubov AV (1986) Tick-Borne Encephalitis and Its Vaccine Prophylaxis, ed Smorodincev AA (Meditsina, Leningrad), pp 190-211.
9. Mandl CW, et al. (1998) Spontaneous and engineered deletions in the 3? noncoding region of tick-borne encephalitis virus: Construction of highly attenuated mutants of a flavivirus. J Virol 72(3):2132-2140.
10. Kofler RM, Heinz FX, Mandl CW (2004) A novel principle of attenuation for the development of new generation live flavivirus vaccines. Arch Virol Suppl 18(18): 191-200.
11. Rumyantsev AA, Chanock RM, Murphy BR, Pletnev AG (2006) Comparison of live and inactivated tick-borne encephalitis virus vaccines for safety, immunogenicity and efficacy in rhesus monkeys. Vaccine 24(2):133-143.
12. Maximova OA, et al. (2008) Comparative neuropathogenesis and neurovirulence of attenuated flaviviruses in nonhuman primates. J Virol 82(11):5255-5268.
13. Wright PF, et al. (2008) Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers. Vaccine 26(7):882-890.
14. Mason PW, Shustov AV, Frolov I (2006) Production and characterization of vaccines based on flaviviruses defective in replication. Virology 351(2):432-443.
15. Ishikawa T, Widman DG, Bourne N, Konishi E, Mason PW (2008) Construction and evaluation of a chimeric pseudoinfectious virus vaccine to prevent Japanese encephalitis. Vaccine 26(22):2772-2781.
16. Suzuki R, Fayzulin R, Frolov I, Mason PW (2008) Identification of mutated cyclization sequences that permit efficient replication of West Nile virus genomes: Use in safer propagation of a novel vaccine candidate. J Virol 82(14):6942-6951.
17. Widman DG, Frolov I, Mason PW (2008) Third-generation flavivirus vaccines based on single-cycle, encapsidation-defective viruses. Adv Virus Res 72:77-126.
18. Ferlenghi I, et al. (2001) Molecular organization of a recombinant subviral particle from tick-borne encephalitis virus. Mol Cell 7(3):593-602.
19. Rumyantsev AA, et al. (2011) Characterization of the RepliVax platform for replication- defective flavivirus vaccines. Vaccine 29(32):5184-5194.
20. Huang CY, et al. (2003) Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J Virol 77(21):11436-11447.
21. Huang CY, Silengo SJ, Whiteman MC, Kinney RM (2005) Chimeric dengue 2 PDK-53/ West Nile NY99 viruses retain the phenotypic attenuation markers of the candidate PDK-53 vaccine virus and protect mice against lethal challenge with West Nile virus. J Virol 79(12):7300-7310.
22. Rumyantsev AA, Murphy BR, Pletnev AG (2006) A tick-borne Langat virus mutant that is temperature sensitive and host range restricted in neuroblastoma cells and lacks neuroinvasiveness for immunodeficient mice. J Virol 80(3):1427-1439.
23. Monath TP, et al. (2002) Clinical proof of principle for ChimeriVax: Recombinant live, attenuated vaccines against flavivirus infections. Vaccine 20(7-8):1004-1018.
24. Guirakhoo F, et al. (2006) Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: Effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 2(2):60-67.
25. Monath TP, et al. (2000) Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: Dose-response effectiveness and extended safety testing in rhesus monkeys. J Virol 74(4):1742-1751.
26. Guirakhoo F, et al. (2000) Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 74(12):5477-5485.
27. Arroyo J, et al. (2004) ChimeriVax-West Nile virus live-attenuated vaccine: Preclinical evaluation of safety, immunogenicity, and efficacy. J Virol 78(22):12497-12507.
28. Monath TP, et al. (2006) A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci USA 103(17):6694-6699.
29. Loew-Baselli A, et al. (2011) Prevention of tick-borne encephalitis by FSME-IMMUN vaccines: Review of a clinical development programme. Vaccine 29(43):7307-7319.
30. Schoendorf I, et al. (2007) Tick-born encephalitis (TBE) vaccination in children: Advantage of the rapid immunization schedule (i.e., days 0, 7, 21). Hum Vaccin 3(2):42-47.
31. Schöndorf I, et al. (2007) Tick-borne encephalitis (TBE) vaccination: Applying the most suitable vaccination schedule. Vaccine 25(8):1470-1475.
32. Hofmeister Y, et al. (2011) Human IgG subclasses: In vitro neutralization of and in vivo protection against West Nile virus. J Virol 85(4):1896-1899.
33. Holzmann H, et al. (1992) Molecular epidemiology of tick-borne encephalitis virus: Cross-protection between European and Far Eastern subtypes. Vaccine 10(5):345-349.
34. Orlinger KK, et al. (2011) A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans. J Infect Dis 203(11):1556-1564.
35. Fritz R, et al. (2012) Quantitative comparison of the cross-protection induced by tickborne encephalitis virus vaccines based on European and Far Eastern virus subtypes. Vaccine 30(6):1165-1169.
36. Kunze U; ISW-TBE (2012) Tick-borne encephalitis (TBE): An underestimated risk. . .still: Report of the 14th annual meeting of the International Scientific Working Group on Tick-Borne Encephalitis (ISW-TBE). Ticks Tick Borne Dis 3:197-201.
37. Donoso Mantke O, Escadafal C, Niedrig M, Pfeffer M; Working Group For Tick-Borne Encephalitis Virus C (2011) Tick-borne encephalitis in Europe, 2007 to 2009. Euro Surveill 16(39):19976.